Suvorexant
Intervention1 paper1 findingPubChem 24965990ChEBI 82698
C · W · M · H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
Against: findings that point the other way from most findings on the same outcome.
No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.
Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.
- Humans1
Associations
1Hospitalization for hip fracture
downin humans1HR 0.57
1 study
Hospitalization for hip fracture
downin humans1HR 0.57
Suvorexant is associated with hospitalization for hip fracture in humans (HR 0.57, 95% CI 0.23–1.44).
HumansNew users; continuous suvorexant treatment compared with Z-drugs, adjusted for confounding and censoring; association not significant1 yearn = 22,377
Lemborexant linked to fewer hip fractures in older adults · Journal of the American Geriatrics Society · 8 Oct 2026
Latest
1Lemborexant linked to fewer hip fractures in older adults
Older adults starting lemborexant had a lower rate of hip fracture than those starting Z-drugs, with a hazard ratio of 0.31 over one year.Older adults starting lemborexant had a lower rate of hip fracture than those starting Z-drugs, with a hazard ratio of 0.31 over one year.